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Abstract
A complex of the Adenovirus (Ad) early region 1b 55-kDa (E1b-55kDa) and early region 4 ORF6 34-kDa (E4-34kDa) proteins promotes
viral late gene expression. E1b-55kDa and E4-34kDa have leucine-rich nuclear export signals (NESs) similar to that of HIV Rev. It was
proposed that E1b-55kDa and/or E4-34kDa might promote the export of Ad late mRNA via their Rev-like NESs, and the transport receptor
CRM1. We treated infected cells with the cytotoxin leptomycin B to inhibit CRM1-mediated export; treatment initially delays the onset of
late gene expression, but this activity completely recovers as the late phase progresses. We find that the E1b-55kDa NES is not required
to promote late gene expression. Previous results showed that E4-34kDa-mediated late gene expression does not require an intact NES
(J. Virol. 74 (2000), 6684–6688). Our results indicate that these Ad regulatory proteins promote late gene expression without intact NESs
or active CRM1.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
The presence of a nucleus in eukaryotic cells has neces-
sitated the development of transport mechanisms for the
movement of proteins and RNAs between the nucleus and
the cytoplasm. RNA export mediated by the human immu-
nodeficiency virus (HIV) Rev protein was one of the first
export pathways to be studied in molecular detail and has
provided important insights into RNA transport mecha-
nisms. HIV Rev binds to a specific Rev responsive element
(RRE) present in the introns of viral RNAs. The Rev
leucine-rich nuclear export signal (NES) binds to a transport
receptor, CRM1, resulting in the export of intron-containing
RNAs from the nucleus to the cytoplasm. These unspliced
RNAs encode additional viral proteins. Thus, the adapter
protein Rev binds to viral RNA and the cellular transport
receptor CRM1. CRM1 then transfers intron-containing
RNP through the nuclear pore complex (reviewed by Cullen,
2000). CRM1 mediates the nuclear export of numerous cellu-
lar proteins with leucine-rich NESs as well as U snRNAs, 5S
rRNA, and the 60S and 40S ribosomal subunits (Cullen, 2000;
Johnson et al., 2002) in uninfected cells. Rev is a viral protein
that is able to shunt unspliced viral RNA into the cellular
CRM1-mediated export pathway.
The export of cellular mRNA is less well understood. In
current models, the protein TAP is thought to be an impor-
tant receptor for mRNA export. TAP is a cellular protein
that binds a stem loop structure known as the constitutive
transport element (CTE) present in the introns of some
retroviral RNAs. The CTE/TAP interaction promotes the
export of unspliced CTE-containing RNAs, just as Rev and
CRM1 promote the export of RRE-containing RNA. TAP is
the human ortholog of the yeast Mex67 protein. These
proteins shuttle between the nucleus and the cytoplasm and
are able to interact with nuclear pore complex proteins.
Genetic studies in yeast and microinjection experiments in
Xenopus laevis oocytes indicate that TAP/Mex67 is a crit-
ical export factor for cellular mRNA (reviewed by Izaur-
ralde, 2001; Zenklusen and Stutz, 2001). CTE containing
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retroviral RNAs access a cellular mRNA export pathway by
directly binding the transport receptor TAP. Thus, the CTE
and Rev both mediate the export of unspliced retroviral
RNA, but they do so by accessing different cellular trans-
port receptors. Recent evidence suggests that there is a
relationship between splicing of cellular mRNA and nuclear
export (reviewed by Dreyfuss et al., 2002; Reed and Hurt,
2002; Reed and Magni, 2002). Splicing deposits a complex
of proteins upstream of the exon–exon junction (LeHir et
al., 2000, 2001). The exon junction complex (EJC) proteins
include Aly/REF, which binds TAP and may be important
for recruiting TAP to mRNAs (Stutz et al., 2000). While
retroviral RNAs containing the CTE can directly access
TAP, at least some cellular mRNAs may recruit Aly/REF
and subsequently TAP, in a splicing-dependent manner
(Reed and Hurt, 2002; Reed and Magni, 2002).
Adenovirus (Ad) gene expression results in the produc-
tion of viral pre-mRNAs, which are polyadenylated and
spliced to mRNAs before they are exported from the nu-
cleus to the cytoplasm. The precise mechanism used by Ad
to export its RNAs is not known. Model RNA substrates
containing exons of the Ad tripartite leader sequence have
been used to identify the location of the EJC after in vitro
splicing (Le Hir et al., 2000). It is not known if EJC proteins
are present on Ad mRNAs synthesized in vivo, or whether
Ad mRNAs use the same export pathway as cellular mRNA.
There are at least two Ad early proteins that contain leucine-
rich NESs that are similar to the HIV Rev NES. These
proteins are the 55-kDa protein produced from early region
1b (E1b-55kDa) and the 34-kDa protein produced from
early region 4 ORF 6 (E4-34kDa). The E1b-55kDa and
E4-34kDa proteins both shuttle between the nucleus and the
cytoplasm (Dobbelstein et al., 1997; Dosch et al., 2001;
Kratzer et al., 2000), and previous genetic studies impli-
cated a complex of these two proteins in promoting viral
mRNA export while preventing cellular mRNA export (re-
viewed by Tauber and Dobner, 2001). The E1b-55kDa
protein was further shown to possess nonspecific RNA-
binding activity (Horridge and Leppard, 1998). These ob-
servations led to models for viral RNA export in which the
NESs of these proteins would promote Ad RNA export by
Rev-like mechanism. It was proposed that the E1b-55kDa/
E4-34kDa complex would associate with viral RNA and
that either the E4-34kDa or the E1b-55kDa NES would link
viral RNA to the export receptor CRM1, thereby mediating
the export of viral RNA from the nucleus to the cytoplasm
(Dobbelstein et al., 1997; Dosch et al., 2001; Kratzer et al.,
2000). If this model for viral late mRNA export is correct,
we would predict (i) that the NESs of the E4-34kDa and/or
the E1b-55kDa proteins should be important for their func-
tion in promoting late gene expression, and (ii) that late
gene expression should be inhibited by the cytotoxin lepto-
mycin B, which covalently modifies CRM1 and prevents its
activity in nuclear transport (Kudo et al., 1999).
Our previous results suggested that the NES of E4-
34kDa was not essential for its function in promoting late
gene expression. We also found that leptomycin B had little
effect on viral late gene expression (Rabino et al., 2000).
However, recent studies demonstrating that E1b-55kDa also
has a Rev-like NES (Kratzer et al., 2000), and that E4-
34kDa export is not completely blocked by leptomycin B
(Dosch et al., 2001), prompted us to reevaluate the role of
CRM1-mediated export for Ad gene expression. Here, we
have tested the effect of preventing CRM1-mediated export
with leptomycin B during both the early and the late phases
of viral infection to better define the role of this transport
pathway in the viral life cycle. We have also studied the
ability of an E1b-55kDa mutant with lesions in its NES to
complement a defective virus mutant that lacks the E1b-
55kDa gene. The results of these studies show that the
E1b-55kDa NES is not critical for complementation and
confirm that CRM1-mediated nuclear export is not essential
for the expression of viral late genes.
Results
Leptomycin B treatment inhibits the cytoplasmic
accumulation of NES- containing proteins without
affecting cell viability
If Ad late RNA export relies on the NES of either the
E4-34kDa or the E1b-55kDa protein, we would expect that
treatment of infected cells with leptomycin B should block
CRM1-dependent transport and thereby prevent late mRNA
transport. Leptomycin B is known from previous studies to
inhibit the cell cycle (Yoshida et al., 1990). To make sure
that our preparation of leptomycin B was functional, we
studied cell growth in cultures treated with leptomycin B.
HeLa cells were cultured in the presence of increasing
concentrations of leptomycin B. At 24, 48, and 72 h post-
treatment, cells were trypsinized and stained with trypan
blue, and the number of viable cells per dish was determined
by counting a fraction of the suspension in a hemocytome-
ter. The results are shown in Fig. 1. We find that 20 nM
leptomycin B was sufficient to inhibit cell growth over a
24 h period. As little as 4 nM leptomycin B was able to
inhibit cell growth over a 48 h period. Cells treated with
leptomycin B were viable for at least 24 h at all concentra-
tions of leptomycin B tested. Cell death was observed in
cultures treated with leptomycin B at 20 and 100 nM for
longer than 24 h. These results indicate that leptomycin B
inhibits cell growth as previously described (Yoshida et al.,
1990), that leptomycin B concentrations between 4 and 100
nM are inhibitory, and that incubations of 24 h or less at
these concentrations do not affect the viability of our cells.
We next studied the cellular location of GFP fusion
proteins in leptomycin B treated cells. Constructs producing
GFP, or GFP fused to the pyruvate kinase nuclear import
signal and a leucine-rich NES from the Epstein–Barr virus
Mta protein (pGL56) (Chen et al., 2001), were transfected
into HeLa cells and the localization of GFP was examined
225C.C. Carter et al. / Virology 315 (2003) 224–233
after treatment with 20 nM leptomycin B for 12 h. The results
are presented in Fig. 2. Leptomycin B had no effect on the
localization of GFP. GFP was detected in both the nucleus and
the cytoplasm of transfected cells that were and were not
treated with leptomycin B (Fig. 2). The NES-containing GFP
fusion protein expressed from pGL56 was detected in both the
nucleus and the cytoplasm in untreated transfected cells. When
these cells were treated with leptomycin B, the NES-contain-
ing GFP protein was detected only in the nucleus. The results
indicate that leptomycin B treatment inhibited the cytoplasmic
accumulation of an NES-containing protein as expected. Iden-
tical results were obtained when transfected cells were treated
for 2–4 h with leptomycin B (data not shown). Taken together,
these results demonstrate that leptomycin B treatment inhibits
the nuclear export of a GFP fusion protein containing a
leucine-rich NES, and that our cells are viable in the presence
of the drug for up to 24 h.
It has been proposed that Ad E1b-55kDa and E4-34kDa
proteins may use their NESs to promote viral late mRNA
export (Dobbelstein et al., 1997; Dosch et al., 2001). We
studied the effect of leptomycin B treatment on the local-
ization of the NES-containing E1b-55kDa protein. HeLa
cells were infected with Ad5 at 40 FFU/cell and subse-
quently were either not treated or treated with 10 nM lep-
tomycin B from 2 to 12 h postinfection (hpi). Cells were fixed
and immunostained with antibody against the viral E1b-
55kDa protein. In untreated cells infected with Ad5, E1b-
55kDa was present in both the nucleus and the cytoplasm.
When cells were cultured with leptomycin B E1b-55kDa
staining was only observed in the nucleus (Fig. 3A). This
result indicates that leptomycin B can prevent localization
of E1b-55kDa to the cytoplasm and is consistent with pre-
vious reports showing that E1b-55kDa uses its leucine-rich
NES to shuttle from the nucleus to the cytoplasm (Kratzer et
al., 2000; Dosch et al., 2001). We next determined how long
cultures needed to be treated with leptomycin B to inhibit
E1b-55kDa export. Cells infected with Ad5 for 12 h were
untreated or treated with 10 nM leptomycin B for the times
indicated (Fig. 3B). We found that a 2-h treatment with
leptomycin B was sufficient to prevent E1b-55kDa local-
ization to the cytoplasm (see also Dosch et al., 2001).
Leptomycin B treatment does not prevent viral late gene
expression
We have found that leptomycin B does not dramatically
affect the production of late proteins when added during the
Fig. 1. Leptomycin B inhibits cell growth in a dose-dependent manner.
HeLa cells were cultured in the presence of 0 (untreated), 1, 4, 20, and 100
nM leptomycin B. At 0, 24, 48 and 72 h posttreatment, cells were treated
with trypsin to release them from the monolayer and stained with trypan
blue, and the number of viable cells per dish was determined by counting
a fraction of the suspension in a hemocytometer.
Fig. 2. Leptomycin B treatment prevents the cytoplasmic localization of a GFP
protein fused to a leucine-rich NES. HeLa cells were transfected with 2.0 g
pEGFP expressing GFP (a, b, e, and f), and pGL56, which expresses GFP
fused to a NLS and a leucine-rich NES (c, d, g, and h). Transfected cells were
either not treated (a–d) or treated with 20 nM leptomycin B (LMB) from 36
to 48 h posttransfection (e–h). Transfected cells were fixed with 4% parafor-
maldehyde and analyzed by microscopy to detect GFP fluorescence (a, c, e,
and g). Phase contrast images are shown in b, d, f, and h. Bar, 10 m.
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late phase of Ad5 infections (Rabino et al., 2000). These
results suggested that CRM1-mediated nuclear export was
not critical for late mRNA accumulation in the cytoplasm
and the synthesis of late proteins. However, it is known that
the E1b-55kDa/E4-34kDa complex has a role in promoting
viral replication and late gene expression that is redundant
with, and is largely compensated for by, the E4 ORF 3
11-kDa protein (E4-11kDa) (Bridge and Ketner, 1989,
1990; Huang and Hearing, 1989). If E4-11kDa promotes
late gene expression independently of the CRM1-mediated
export pathway, then it is possible that CRM1-mediated
export of E1b-55kDa and/or E4-34kDa would be important
for late gene expression in mutants lacking the E4-11kDa
gene. We studied the effect of leptomycin B on late gene
expression by wild-type Ad5, and E4 mutant H5ilE4I,
which carries the cDNA for the E4-34kDa protein in place
of the wild-type E4 coding region. This virus lacks the gene
for the E4-11kDa protein, but is similar to wild-type Ad for
viral growth (Hemstrom et al., 1988). Cells were infected
with Ad5 and H5ilE4I, and either treated or not treated with
10 nM leptomycin B from 12 to 24 hpi. Extracts were
prepared from the infected cells and subjected to Western
blotting experiments using an antibody that detects the viral
late proteins penton and fiber. We find that leptomycin B
had no effect on late protein production in either Ad5 or
H5ilE4I (Fig. 4, top). This result indicates that even in the
absence of redundant E4-11kDa functions, inhibiting
CRM1-mediated export with leptomycin B has little effect
on late gene expression when added during the late phase. In
contrast, leptomycin B did affect the accumulation of late
proteins of both Ad5 and H5ilE4I when added to infected
cultures from 2 to 12 hpi (Fig. 4, bottom).
We next performed a time course to determine if late
gene expression was defective or delayed when infected
cells were incubated with leptomycin B throughout the early
phase. Cells infected with Ad5 were untreated or treated
with 10 nM leptomycin B from 2 hpi to the times indicated.
Protein extracts were prepared and subjected to Western
blotting. Although late gene expression in leptomycin B
treated cultures was reduced at 12 hpi, it had substantially
recovered by 16 hpi (Fig. 5A). Southern blotting experi-
ments were then performed to examine the effect of lepto-
mycin B treatment on the accumulation of viral DNA. The
results shown in Fig. 5B indicated that viral DNA replica-
tion was slightly reduced in cells treated with leptomycin B
Fig. 3. Leptomycin B prevents cytoplasmic accumulation of the E1b-
55kDa protein. (A) Cells were infected with Ad5 at 40 FFU/cell and were
either untreated (a and b) or treated with 10 nM leptomycin B from 2 to 12
hpi (c and d). Cells were fixed with paraformaldehyde at 12 hpi and
immunostained with MAb 2A6 to detect the viral E1b-55kDa protein (b, d
and f). Phase contrast images of the cells are shown in a, c, and e. e and f
show a cell from an untreated and uninfected (UI) culture. Bar, 10 m. (B)
Uninfected (a) and cells infected with Ad5 at 40 FFU/cell (b-f) were
untreated (a and b) or treated with 10 nM leptomycin B (LMB) for the
times indicated before fixing at 12 hpi and immunostaining with MAb 2A6
to detect E1b-55kDa.
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from 2 to 12 hpi but had recovered completely by 16 hpi.
This suggests that leptomycin B treatment during the early
phase may delay the onset of the late phase. We think it is
likely that once viral DNA replication recovers, late gene
expression recovers shortly thereafter.
We examined the levels of the viral early region 2 72-
kDa (E2-72kDa) and E1b-55kDa proteins to see if the delay
in the onset of late gene expression caused by leptomycin B
treatment stemmed from an effect on early protein expres-
sion. Cells were infected with Ad5 and were either not
treated or treated with leptomycin B from 2 hpi infection to
the times indicated. Protein extracts were prepared and
subjected to Western blotting using antibodies that detect
the E1b-55kDa protein or the viral E2-72kDa DNA-binding
protein. We did not observe any dramatic effect on levels of
these early proteins when cells were cultured with leptomy-
cin B from 2 to 16 hpi (Fig. 5C). These results suggest that
the leptomycin B mediated delay in the onset of the late
phase is not the result of reduced early protein levels.
E1b-55kDa proteins with or without an intact NES
complement late gene expression of H5dl1016 in the
absence of CRM1-mediated export
We previously found that the E4-34kDa NES was not
required for late gene expression (Rabino et al., 2000), but
the importance of the E1b-55kDa NES for late gene expres-
sion has not yet been addressed. We constructed an E1b-
55kDa expression plasmid with three leucine-to-alanine
changes in its NES (see Materials and methods). We then
examined the localization of wild-type and NES-mutant
E1b-55kDa proteins transiently expressed in HeLa cells
(Fig. 6A). Wild-type E1b-55kDa was found primarily in the
cytoplasm with concentration in large perinuclear bodies
(Zantema et al., 1985), while localization of the E1b-55kDa
NES mutant protein was restricted to the nucleus. This
indicated that mutations in the NES prevented the cytoplas-
mic localization of the protein as was shown previously
(Kratzer et al., 2000). When transfected cells were cultured
with leptomycin B, both proteins were found in the nucleus,
further indicating that the cytoplasmic localization of the
wild-type E1b-55kDa protein is the result of CRM1-medi-
ated nuclear export. We next performed complementation
experiments in which HeLa cells were first transfected with
expression constructs producing either wild-type E1b-
55kDa or NES mutant E1b-55kDa and subsequently in-
fected with H5dl1016 (Fig. 6B). H5dl1016 carries muta-
tions affecting the genes of the E1b-55kDa and E4-11kDa
proteins. This mutant is defective for the ability to replicate
DNA and express its late genes since it lacks the E1b-55kDa
partner of the E1b-55kDa/E4-34kDa complex as well as the
redundant functions of the E4-11kDa protein (Bridge and
Ketner, 1990). We found that the E1b-55kDa NES mutant
was able to stimulate late gene expression by H5dl1016 as
well as the wild-type protein. A transfected construct pro-
ducing GFP had no effect on late gene expression by
H5dl1016 as expected. Mutant and wild-type E1b-55kDa
expression constructs were also able to complement late
gene expression in the presence of leptomycin B (Fig. 6B).
NES mutant and wild-type E1b-55kDa genes were ex-
pressed from transfected constructs in these assays and are
therefore not regulated as they would be if they were ex-
pressed from the viral genome. Nevertheless, we have ob-
Fig. 4. The affect of leptomycin B treatment on late gene expression by
Ad5 and H5ilE4I. Cells were either uninfected (UI) or infected with Ad5
and H5ilE4I (I) at 40 FFU/cell, and subsequently either not treated or
treated with 10 nM leptomycin B (LMB) for the times indicated. Extracts
were prepared from the infected cells and subjected to Western blotting
experiments using an antiserum that detects the viral late proteins penton
and fiber.
Fig. 5. Leptomycin B treatment delays but does not prevent Ad late gene
expression. We performed a time course to study the effect of leptomycin
B treatment on the accumulation of viral late proteins (A), viral DNA (B),
and viral early proteins (C). Uninfected (UI) cells or cells infected with
Ad5 at 40 FFU/cell were untreated or treated with 10 nM leptomycin B
(LMB) from 2 hpi to the times indicated. Protein extracts were prepared
from a fraction of each culture; total cellular DNA was prepared from the
remaining fraction. (A) Western blotting was performed on the protein
samples using antiserum raised against the viral late proteins penton and
fiber. (B) DNA samples were digested with EcoR1, fractionated on a 1.4%
agarose gel, and then transferred to a nylon membrane for Southern
hybridization. Random-primed Ad5 DNA was used as a probe. The posi-
tions of the DNA fragments corresponding to EcoR1-digested Ad5 are
indicated with arrowheads. (C) Western blotting was performed on protein
samples using antibodies that detect the E1b-55kDa protein or the viral
E2-72kDa DNA binding protein.
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served E1b-55K by immunofluorescence microscopy in
transfected/infected cells that are positive for late proteins
and have complemented late gene expression. We find that
the intensity of E1b-55K staining in these cells is similar to
that observed in cells infected for 24 h with wild-type Ad5
(data not shown). This suggests that the E1b-55K protein is
not dramatically overexpressed in the cells that have com-
plemented late gene expression. Our data show that neither
the E1b-55kDa NES nor an active CRM1-mediated export
pathway was essential for the ability of the E1b-55kDa
protein to stimulate late gene expression in a complemen-
tation assay.
Discussion
Our previous results suggested that the NES of the E4-
34kDa protein was not critical for its function in comple-
menting late gene expression. These results were confirmed
in virus-infected cells by blocking the activity of the CRM1
transport receptor with leptomycin B. Leptomycin B treat-
ment did not dramatically affect Ad late gene expression,
suggesting that late gene expression requires neither an
intact E4-34kDa NES nor a functional CRM1 export path-
way (Rabino et al., 2000). In contrast, Weigel and Dobbel-
stein (2000) found that the E4-34kDa NES is important for
facilitating viral DNA replication, late gene expression, and
viral growth. Although Dobbelstein et al. (1997) were able
to show that the E4-34kDa NES fused to GST could medi-
ate its export, Dosch et al. (2001) were unable to demon-
strate that the E4-34kDa NES could support nuclear export
when fused to GFP. Furthermore, Dosch et al. (2001) found
that leptomycin B did not prevent E4-34kDa nuclear export.
In our experiments, leptomycin B inhibits but does not
block E4-34kDa shuttling from the nucleus to the cyto-
plasm, raising the possibility that E4-34kDa may exit the
nucleus by more than one export pathway (Rabino et al.,
2000). Finally, the discovery of an NES in the E1b-55kDa
protein (Kratzer et al., 2000) raised the possibility that
E1b-55kDa might mediate RNA export independently of
E4-34kDa (Dosch et al., 2001).
The conflicting reports on the function and activity of the
E4-34kDa NES (Bridge, 2000; Tauber and Dobner, 2001),
and the observation that the E1b-55kDa protein has an
independent NES, prompted us to reexamine the role of
CRM1-mediated export for viral replication and late gene
expression. Blocking CRM1-mediated export with leptomy-
cin B prevents the cytomplasmic localization of E1b-55kDa
and a GFP fusion protein containing a leucine-rich NES
(Figs. 2 and 3). During prolonged leptomycin B treatments
of 12–24 h, the E1b-55kDa protein remained nuclear (Fig. 3
and data not shown). Leptomycin B treatment delayed but
did not block the transition to the late phase when it was
added to cultures directly after infection (Figs. 4 and 5).
Weigel and Dobbelstein (2000) identified a role for the
E4-34kDa NES in the onset of viral DNA replication. It is
possible that the delay we observe in the onset of the late
phase is the result of inhibiting the nuclear export of the
E4-34kDa or E1b-55kDa proteins. However, leptomycin B
Fig. 6. An E1b-55kDa protein lacking an intact NES promotes viral late
gene expression in the presence or absence of leptomycin B. (A) Plasmids
expressing wild-type E1b-55kDa or E1b-55kDa with a mutant NES were
used to transfect HeLa cells. Immunofluorescence staining was performed
with MAb 2A6 to detect the E1b-55kDa protein. The results show the
localization of wild-type (WT, a, b, e, and f) and NES mutant (NES-, c, d,
g, and h) E1b-55kDa proteins in untreated cells (a–d) and in cells treated
from 36 to 48 h posttransfection with 20 nM leptomycin B (LMB, e–h).
Bar, 10 m. (B) A complementation assay was performed by transfecting
HeLa cells with constructs producing wild-type E1b-55kDa, a E1b-55kDa
NES mutant, or GFP. Transfected cells were subsequently infected with
H5dl1016, a defective virus lacking the E1b-55kDa gene, at a multiplicity
of 5 FFU/cell. The levels of E1b-55kDa and viral late proteins produced in
the transfected/infected cells were measured by Western blotting. MAb
2A6 was used to detect E1b-55kDa and antisera raised against penton and
fiber was used to detect viral late proteins. The levels of these proteins
detected in extracts from uninfected (UI), Ad5, and H5dl1016-infected
cells are shown in the first three lanes. The remaining lanes show E1b-
55kDa and late proteins levels in extracts prepared from cells transfected
with plasmids expressing the proteins indicated and subsequently infected
with H5dl1016. Some transfected/infected cells were treated with 20 nM
leptomycin B (LMB) from 12 to 24 hpi where indicated.
229C.C. Carter et al. / Virology 315 (2003) 224–233
treatment can also affect the cell cycle (Yoshida et al.,
1990), and experiments by Ornelles and colleagues have
suggested that the stage of the cell cycle during infection
can affect replication of at least some Ad mutants (Goodrum
and Ornelles, 1997, 1999). We do not presently know if the
leptomycin B mediated delay in the onset of late gene
expression is a direct effect on the export of viral NES-
containing proteins, or, if it is a result of blocking the export
of other cellular NES-containing proteins, and subsequent
effects on the cell cycle and/or other cellular activities.
Despite the initial delay, DNA replication and late gene
expression in Ad-infected cells cultured in the presence of
leptomycin B had completely recovered by 16 hpi (Fig. 5).
Leptomycin B had no effect on the accumulation of late
proteins when it was added at the onset of the late phase
(Fig. 4), as we have previously shown (Rabino et al., 2000).
Significantly, leptomycin B did not inhibit late protein pro-
duction by H5ilE4I (Fig. 4). Genetic studies have shown
that the functions of the E1b-55kDa/E4-34kDa complex are
at least partially redundant with the function of the E4-
11kDa protein (Bridge and Ketner 1989, 1990; Huang and
Hearing 1989). Since H5ilE4I lacks E4-11kDa, our results
suggest that even in the absence of redundant functions
provided by the E4-11kDa protein, the CRM1-mediated
export pathway was not essential for continued expression
of viral genes during the late phase. Furthermore, since
leptomycin B treatment restricts E1b-55kDa localization to
the nucleus (Kratzer et al., 2000; Dosch et al., 2001; Fig. 3),
our results predict that the export activity of the E1b-55kDa
protein should not be critical for its function in late gene
expression. We tested the role of the E1b-55kDa NES in
complementation studies and found that NES mutations did
not affect the ability of E1b-55kDa to stimulate late gene
expression of H5dl1016 in either the presence or the ab-
sence of leptomycin B treatment (Fig. 6B). We have not
identified a critical role for the NESs of either the E4-34kDa
(Rabino et al., 2000) or the E1b-55kDa protein (Fig. 6B) in
complementation studies. A limitation of this assay is that
expression of the NES mutant E1b-55kDa and E4-34kDa
genes is not regulated by expression from their endogenous
promoters within the context of the viral genome. However,
the results of the complementation studies are in complete
agreement with our observation that inhibiting NES-medi-
ated export with leptomycin B does not dramatically affect
viral late gene expression either in the complementation
assay (Fig. 6B) or during virus infection (Fig. 4). Taken
together, these results strongly support our previous obser-
vation that the CRM1-mediated export pathway is not re-
quired for viral late gene expression (Rabino et al., 2000)
and suggest that other activities of the E4-34kDa and E1b-
55kDa proteins are important for their function in promot-
ing viral late gene expression.
E4-34kDa and E1b-55kDa form a complex with a cellu-
lar ubiquitin ligase that is able to target specific cellular
proteins for proteasome-mediated degradation (Harada et
al., 2002; Querido et al., 2001). Known targets of the E1b-
55kDa/E4-34kDa complex include the cell-cycle regulatory
protein p53 (Querido et al., 2001) and cellular DNA double-
strand break repair (DSBR) proteins (Stracker et al., 2002).
We have performed a mutational analysis of the E4-34kDa
protein and found that the same regions of the protein that
are critical for directing proteasome-mediated degradation
of p53 are also important for complementing late gene
expression of a defective mutant lacking the E4-34kDa
gene. We used proteasome inhibitors to demonstrate that
complementation depended on the presence of functional
proteasomes (K.A. Corbin-Lickfett and E. Bridge, submit-
ted for publication). These results suggest a link between the
ability of the E4-34kDa protein to promote late gene ex-
pression and its ability to target cellular proteins for protea-
some-mediated degradation. However, we also find that
E4-34kDa complements late gene expression independently
of cellular p53 status. This suggests that degradation of p53
is not the only function of the E1b-55kDa/E4-34kDa com-
plex in promoting late gene expression (K. A. Corbin-
Lickfett and E. Bridge, submitted for publication). It is
possible that degradation of cellular DSBR proteins by the
E1b-55kDa/E4-34kDa complex is important for promoting
late gene expression. When the cellular double-stranded
break repair system is active, it ligates the ends of linear
double-stranded viral DNA to each other, forming genome
concatemers. The E1b-55kDa/E4-34kDa complex and the
E4-11kDa proteins are able to prevent ligation of viral
genomes into concatemers (Boyer et al., 1999; Stracker et
al., 2002; Weiden and Ginsberg, 1994). It is not known if
the formation of DNA concatemers interferes with subse-
quent steps in viral late gene expression. Alternatively,
additional, and as yet unidentified, proteins targeted for
degradation by the E1b-55kDa/E4-34kDa complex could
play an important role in selective viral RNA export during
the late phase. Numerous cellular RNA-binding proteins are
important for the metabolism and export of host RNA (re-
viewed in Dreyfuss et al., 2002). Although to date no pro-
teins involved in RNA stability or export have been iden-
tified as targets for E1b-55kDa/E4-34kDa-mediated
degradation, this possibility could provide an attractive ex-
planation for the role of the complex in promoting viral late
gene expression while inhibiting the export of newly syn-
thesized host mRNA.
Our results indicate that the CRM1-mediated export
pathway is unlikely to be the only export pathway accessed
by viral late mRNA. CRM1 exports a variety of shuttling
proteins, and some cellular RNAs, but it is not likely to be
the major transport receptor used to export cellular mRNA
(Gallouzi and Steitz, 2001; Izaurralde, 2001). Ad mRNAs
are capped, spliced, and polyadenylated by the host post-
transcriptional processing machinery and are therefore
structurally very similar to cellular mRNA. How are viral
late mRNAs identified and selectively exported from the
nucleus during the late phase? One possibility is that the
activity of virus gene products shuts down cellular mRNA
export pathways, while virus mRNAs are able to access a
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separate pathway. Another possibility is that newly synthe-
sized virus mRNAs have exclusive access to cellular mRNA
export pathways during the late phase of infection. Ornelles
and Shenk (1991) proposed that limiting cellular factors
recruited to sites of viral RNA transcription might promote
viral mRNA export and be unavailable for promoting cel-
lular mRNA export. In this model, host factors are selec-
tively recruited to newly synthesized viral mRNA. Presum-
ably the activity of viral early proteins would promote the
selective interaction of these host factors with viral RNA.
Interestingly, Chen et al. (2002) recently showed that the
herpesvirus ICP27 protein interacts with, and is able to
recruit, the EJC protein Aly/REF to sites of viral transcrip-
tion. Since Aly/REF interacts with the cellular transport
receptor TAP, these results suggest that ICP27 is able to
target unspliced herpesvirus RNA to the TAP-mediated
cellular export pathway. It remains to be determined
whether Ad early proteins will recruit cellular export factors
to Ad late transcripts in an analogous manner.
Materials and methods
Cell culture and viruses
HeLa cells were grown in monolayer cultures in Dulbec-
co’s modified Eagle’s medium supplemented with 10% fetal
calf serum in 5% CO2 at 37°C. Wild-type Ad5 was origi-
nally from J. Williams. H5ilE4I carries a cDNA expressing
the E4 ORF6 34-kDa protein in place of the E4 region
(Hemstrom et al., 1988), and therefore, lacks the gene for
the E4-11kDa protein. H5dl1016 (Bridge and Ketner, 1990)
lacks the genes coding for E1b-55kDa and E4-11kDa.
H5dl1016 was propagated in monolayers of HEK 293 cells.
Virus titers, expressed as fluorescence-forming units (FFU)/
ml, were determined on W162 cells for Ad5 and H5ilE41,
as described (Philipson, 1961). Titers of Ad5 and H5dl1016
were determined in HEK 293 cells.
Plasmids and transfections
The GFP expressing control plasmid, pEGFP, was from
Clontech. pGL56 expresses GFP fused to an NLS from
pyruvate kinase and an NES derived from the Epstein–Barr
virus Mta protein (Chen et al., 2001) and was a gift from
S.D. Hayward. The wild-type Ad2 E1b-55kDa gene cloned
into pcDNA3.1 was a gift from Goran Akusjarvi (Punga and
Akusjarvi, 2000). We used PCR-based mutagenesis to con-
struct a vector that expresses the E1b-55kDa protein carry-
ing a mutation in its NES. We amplified a fragment of the
wild-type clone using a 3 primer 5-TAGAAGGCA-
CAGTCGAGG-3 that overlapped with the reverse priming
site of pcDNA3.1 located downstream of the 3 end of the
gene. The 5 mutagenic oligonucleotide primer 5-
GAATGTTGTACAGGTGGCTGAAGCGTATCCGGAAG-
CGAGACGCATTGCGAC-3 contains the BsrGI restriction
site at base-pair (bp) 230 and the NES at bp 246–279 of the
E1b-55kDa gene. The sequence of the primer was designed to
convert three leucines in the NES (L83, L87, and L91) to
alanines. The fragment amplified by PCR was digested with
XhoI, which cuts just downstream of the gene in the pcDNA3.1
multiple cloning site, and BsrGI and cloned back into the
wild-type E1b-55kDa vector cut with XhoI-BsrGI. Clones con-
taining NES mutation in the E1b-55kDa gene were identified
by the presence of a BspEI restriction site introduced into the
mutagenic oligo. The sequence of the cloned fragment with the
expected mutations was confirmed by nucleotide sequence
analysis using an automated DNA sequencer (ABI PRISM).
Expression constructs were transfected into HeLa cells using
the Effectene transfection reagent according to instructions
provided by the manufacturer (Qiagen).
Immunostaining
Infected or transfected HeLa cells grown on coverslips
for the times indicated were fixed by incubating them with
1% paraformaldehyde in PBS for 3–5 min, extracting with
0.5% Triton X-100 in PBS for 15 min, and postfixing for 10
min in 4% paraformaldehyde in PBS. GFP distribution was
analyzed directly after fixing the cells in 4% paraformalde-
hyde. The intracellular distribution of E1b-55kDa was an-
alyzed by immunostaining of the fixed cells using anti-E1b-
55kDa monoclonal antibody (MAb) 2A6, which recognizes
an epitope located within the N-terminal 180 amino acids of
the protein (Sarnow et al., 1984) and FITC-conjugated anti-
mouse Ig as the secondary antibody (Southern Biotechnol-
ogy Associates Inc.).
Western blotting
Infected, transfected, or transfected/infected cultures
were washed twice with ice-cold phosphate-buffered saline
(PBS) and then lysed in 250–300 L of lysis buffer [150
mM NaCl, 50 mM Tris pH 8.0, 5 mM EDTA, 0.15%
(vol/vol) Nonidet P-40, 0.1 mM DTT, and 5 g/ml aproti-
nin and leupeptin]. Cell lysates were sonicated and total
protein was measured by Bradford assay using Coomassie
Plus protein reagent (Pierce) according to the manufactur-
er’s specifications. Equal amounts of total protein were
subjected to sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS–PAGE) using 12% polyacrylamide
gels. Proteins were transferred to enhanced chemilumines-
cence (ECL) nitrocellulose (Amersham Pharmacia Biotech)
overnight and the membranes were probed with primary
antibodies diluted in 5% nonfat dry milk. Primary antibod-
ies used included rabbit antiserum against viral late proteins
penton and fiber (Ulf Pettersson), E2-72kDa DNA binding
protein (Tomas Linne´), and MAb2A6 against E1b-55kDa
(from A. Levine). A 1:1500 dilution of peroxidase-coupled
anti-mouse or anti-rabbit secondary antibody (Amersham
Pharmacia Biotech) was used for detection. The membranes
were incubated with ECL Western Blotting Detection Re-
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agents according to the manufacturer’s instructions (Amer-
sham Pharmacia Biotech) and exposed to autoradiography
film.
Southern blotting
Total DNA was prepared from infected and uninfected
cells (Bridge and Ketner, 1989). Ten micrograms of each
sample DNA was digested with EcoRI, and the resulting
fragments were separated according to size by electrophore-
sis through an agarose gel. The fractionated DNA was then
transferred to Hybond-N nylon membrane (Amersham
Pharmacia Biotech) for Southern blotting. Purified Ad5
DNA was used for random priming to generate 32P-labeled
probe. The viral DNA fragments hybridizing to the probe
were visualized by autoradiography.
Drug treatment
Leptomycin B was a gift from Barbara Wolff and was
used for the times and concentrations indicated in the fig-
ures.
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